Pharmaceutical Executive-08-01-2022

Failed efforts do not overshadow field’s progress, resolve.

A review of pharma and biotech equity market, IPO, and M&A trends and outputs through the first half of 2022—and implications for the future as disruptions continue to have an impact.

How one company in particular has adjusted its internal and customer-facing strategies in compliance training amid today’s heightened business-risk climate.

The BCG Market Access Roundtable outlines the new and advanced access competencies required to enable functional operationalization and delivery of this critical role in biopharma—today a key strategic partner in achieving overall business goals.

Major stakeholders—including policymakers, public-private interests, and academia—are increasingly embracing the potential of proteomics technology in reshaping diagnostics and patient care.

Innovative and continuous remote patient monitoring, along with AI-based predictive analytics, are advancing progress toward replacing the one-size-fits-all, population-driven vaccination model.

Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?

The road to precision medicine as a fixture in healthcare delivery is still a journey, but recent advances and new understandings in gene profiling, biomarker development, and AI and data analytics are steadily bringing these therapies closer to the individual patient every day.

Marie-France Tschudin, president, innovative medicines international, and chief commercial officer at Novartis, taps into life lessons to help bring therapies to people in novel ways­.

A look at the driving factors behind renewed optimism.

The technology is not just about digital enablement anymore.

How principles of both can help companies navigate future storms.

Proposed SoHO reform elicits wide support, but risks acknowledged.

Personalized medicine here to stay after massive uptick in 2021 approvals.

Click the title above for a link to open the Pharmaceutical Executive August 2022 issue in an interactive PDF format.

Agency partners with patent office in addressing anticompetitive practices.